28 Participants Needed

Smartphone App for Post-Surgery Care in Bladder Cancer

Age: 18+
Sex: Any
Trial Phase: Academic
Sponsor: University of Michigan Rogel Cancer Center
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

Trial Summary

What is the purpose of this trial?

Hospital readmissions are common after major cancer surgery, leading to poorer patient outcomes, increased mortality and additional costs. In this study, Clinical and Engineering Approaches to Readmission (CLEAR) Care Companion Application, investigators aim to utilize a smartphone application that tracks concerning postoperative symptoms and provides educational interventions to determine if this can minimize delays in communication between patients and medical providers, increase patient satisfaction with the care received, and reduce or lessen the severity of readmissions.

Do I need to stop my current medications for this trial?

The trial protocol does not specify whether you need to stop taking your current medications.

What data supports the idea that Smartphone App for Post-Surgery Care in Bladder Cancer is an effective treatment?

The available research shows that mobile health apps can improve patient outcomes in various types of cancer care. For example, a study on gynecologic oncology patients found that using a mobile health app improved their recovery after surgery. Another study on complex abdominal surgery patients is testing a similar app to see if it can reduce hospital readmissions, which are costly and common. Although these studies are not specifically about bladder cancer, they suggest that using a smartphone app for post-surgery care could help patients recover better and avoid returning to the hospital.12345

What safety data exists for the smartphone app used in post-surgery care for bladder cancer?

The provided research does not directly mention safety data for the CLEAR Care Companion app or its other names. However, it highlights the development and evaluation of similar mobile health technologies aimed at improving post-surgical care and reducing readmissions. The studies focus on usability, patient engagement, and transitional care improvements, but specific safety data for the app in question is not detailed.25678

Is the treatment in the trial 'Smartphone App for Post-Surgery Care in Bladder Cancer' promising?

Yes, using a smartphone app for post-surgery care in bladder cancer is promising because similar apps have improved patient engagement and care after surgeries in other types of cancer, like gynecologic and colorectal cancers. These apps help patients manage their recovery better and stick to their treatment plans, which can lead to better health outcomes.1591011

Research Team

JM

Jeffery Montgomery, M.D.

Principal Investigator

University of Michigan Rogel Cancer Center

Eligibility Criteria

This trial is for English-speaking bladder cancer patients at the University of Michigan who are undergoing radical cystectomy. Participants must have access to a smartphone or tablet with internet to use the CLEAR Care Companion app.

Inclusion Criteria

I am having bladder removal surgery with reconstruction.
Access to compatible smartphone or tablet device
Patient at the University of Michigan (Michigan Medicine)

Exclusion Criteria

Patients without access to a smart phone or tablet with internet capacity
I do not speak English.

Treatment Details

Interventions

  • CLEAR Care Companion (CC) application
Trial OverviewThe study tests if a smartphone application, which tracks symptoms and provides educational content after major cancer surgery, can improve communication with doctors, patient satisfaction, and reduce hospital readmissions.
Participant Groups
1Treatment groups
Experimental Treatment
Group I: CLEAR CCExperimental Treatment1 Intervention
Patients use CLEAR CC application with Smartphone or Tablet

Find a Clinic Near You

Who Is Running the Clinical Trial?

University of Michigan Rogel Cancer Center

Lead Sponsor

Trials
303
Recruited
20,700+

Findings from Research

The use of a mobile health patient engagement technology (PET) in gynecologic oncology patients led to a significant reduction in hospital length of stay (LOS), averaging 2.9 days compared to 3.6 days in the control group.
Patients using the PET also experienced a 50% lower readmission rate (4.3% vs. 8.6%), indicating that the technology effectively improved postoperative outcomes and patient engagement.
Use of a mobile health patient engagement technology improves perioperative outcomes in gynecologic oncology patients.Boitano, TKL., Gardner, A., Chu, DI., et al.[2023]
This study will evaluate the effectiveness of the MobiMD mobile app in reducing hospital readmissions for 300 patients who have undergone complex abdominal surgery, comparing it to standard care.
The app allows for daily monitoring of vital signs and symptoms, with the goal of improving transitional care and potentially lowering readmission rates within 30 days post-surgery.
Protocol for the MobiMD trial: A randomized controlled trial to evaluate the effect of a self-monitoring mobile app on hospital readmissions for complex surgical patients.Diehl, TM., Barrett, JR., Abbott, DE., et al.[2023]
The self-assessment smartphone app alerted 72.6% of users about concerning symptoms related to tobacco-induced diseases, with current smokers showing a higher incidence of symptoms like fatigue and cough, indicating a significant awareness of health issues.
During the study, the incidence of early-stage lung cancer (stages 1 and 2) increased to 24% among users, compared to 9% in the previous year, suggesting that the app may enhance early detection of lung cancer and encourage smoking cessation efforts.
Use of a Smartphone Self-assessment App for a Tobacco-Induced Disease (COPD, Cardiovascular Diseases, Cancer) Screening Strategy and to Encourage Smoking Cessation: Observational Study.Stavaux, E., Goupil, F., Barreau, G., et al.[2023]

References

Use of a mobile health patient engagement technology improves perioperative outcomes in gynecologic oncology patients. [2023]
Protocol for the MobiMD trial: A randomized controlled trial to evaluate the effect of a self-monitoring mobile app on hospital readmissions for complex surgical patients. [2023]
Use of a Smartphone Self-assessment App for a Tobacco-Induced Disease (COPD, Cardiovascular Diseases, Cancer) Screening Strategy and to Encourage Smoking Cessation: Observational Study. [2023]
Pilot implementation to assess the feasibility and care team impact of an app-based interactive care plan to remotely monitor breast cancer survivors. [2022]
Development of a Remote Monitoring Application to Improve Care and Support Patients in the First 30 Days Following Colorectal Cancer Surgery. [2023]
Patient and provider perceptions on utilizing a mobile technology platform to improve surgical outcomes in the perioperative setting. [2021]
A Web-Based Cancer Self-Management Program (I-Can Manage) Targeting Treatment Toxicities and Health Behaviors: Human-Centered Co-design Approach and Cognitive Think-Aloud Usability Testing. [2023]
Report on the NCCN Third Annual Patient Safety Summit. [2019]
Predictors of Adherence to Cancer-Related mHealth Apps in Cancer Patients Undergoing Oncological or Follow-Up Treatment-A Scoping Review. [2023]
Patients' experiences of using an e-Health tool for self-management support after prostate cancer surgery: a deductive interview study explained through the FITT framework. [2021]
A Smartphone-Based App to Improve Adjuvant Treatment Adherence to Multidisciplinary Decisions in Patients With Early-Stage Breast Cancer: Observational Study. [2021]